<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Schizotypal personality disorder: Treatment overview</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Schizotypal personality disorder: Treatment overview</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Schizotypal personality disorder: Treatment overview</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel R Rosell, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew Skodol, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Friedman, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 15, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H350993230"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Schizotypal personality disorder is a chronic disorder with manifestations beginning in childhood and adolescence. Phenomenologic characteristics of the disorder include cognitive-perceptual problems (eg, magical thinking and paranoia), oddness (eg, odd rapport, affect, and speech), and interpersonal problems (eg, social anxiety and a lack of close friends).</p><p>Schizotypal personality disorder is underrecognized, and its treatment is understudied. The lifetime prevalence of schizotypal personality disorder in the general United States population has been estimated at just under 4 percent. The disorder is associated with significant disability, as well as a wide range of psychiatric comorbidities. Schizotypal personality disorder is challenging to treat.</p><p>This topic reviews our approach to selecting treatments for schizotypal personality disorder, as well as pharmacotherapy for the disorder. The epidemiology, pathogenesis, clinical manifestations, course, and diagnosis of schizotypal personality disorder, as well as psychotherapy for the disorder, are reviewed separately. Establishing and maintaining a therapeutic relationship in patients with personality disorders are also reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/14771.html" rel="external">"Schizotypal personality disorder: Epidemiology, pathogenesis, clinical manifestations, course, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/112012.html" rel="external">"Schizotypal personality disorder: Psychotherapy"</a> and  <a class="medical medical_review" href="/z/d/html/6617.html" rel="external">"Overview of personality disorders"</a> and  <a class="medical medical_review" href="/z/d/html/16980.html" rel="external">"Approaches to the therapeutic relationship in patients with personality disorders"</a>.)</p><p class="headingAnchor" id="H3594730008"><span class="h1">INITIATING TREATMENT</span><span class="headingEndMark"> — </span>The priorities of the initial treatment visits for individuals with schizotypal personality disorder include establishing an alliance, reviewing the individuals symptoms and level of functioning, assessing the individuals capacity to critically examine thoughts, and establishing treatment plan and goals. (See  <a class="medical medical_review" href="/z/d/html/112012.html" rel="external">"Schizotypal personality disorder: Psychotherapy", section on 'Initiating a psychotherapeutic relationship'</a>.)</p><p class="headingAnchor" id="H639619313"><span class="h1">PSYCHOTHERAPY AS THE PRIMARY INTERVENTION</span><span class="headingEndMark"> — </span>For individuals with schizotypal personality disorder, we suggest first-line treatment with a long-term, psychodynamically informed psychotherapy. We prefer to use pharmacologic treatment for targeted symptom relief in the context of psychotherapy. (See <a class="local">'As needed symptom-targeted pharmacotherapy'</a> below.)</p><p class="headingAnchor" id="H20134076"><span class="h2">Selection of psychotherapy</span><span class="headingEndMark"> — </span>There are limited data to support the use of a specific type of psychotherapy in the treatment of schizotypal personality disorder [<a href="#rid1">1</a>]. Our choice is based on our clinical experience. We favor the use of supportive, supportive-expressive, or exploratory/insight-oriented psychotherapies.</p><p>We base our specific choice of psychotherapy on the individual’s level of impairment, ability to critically examine thoughts, and capacity to tolerate negative emotions. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lower functioning, less introspective</strong> – For these individuals, we favor a supportive psychotherapy that maintains stability and mitigates symptomatic exacerbation. These individuals are typically highly impaired and have chronic symptoms and are less able to critically examine thoughts. Technique and goals of this therapy and further description of individuals it is best suited to are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/112012.html" rel="external">"Schizotypal personality disorder: Psychotherapy", section on 'Less introspective, lower functioning individuals'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intermediate level of functioning and introspection</strong> – For these individuals, we favor supportive-expressive therapy. These individuals are typically superficially well adjusted, able to live independently and often sustain gainful employment. Technique and goals of this therapy and further description of individuals it is best suited to are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/112012.html" rel="external">"Schizotypal personality disorder: Psychotherapy", section on 'Intermediate introspection and functioning'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Higher functioning, more introspective</strong> – For these individuals, we favor exploratory, insight-oriented psychotherapy. These individuals are generally able to critically examine thoughts and may be able to explore unconscious thoughts. These individuals are typically able to maintain a job and live independently. The techniques and goals of this therapy and further description of individuals it is best suited to are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/112012.html" rel="external">"Schizotypal personality disorder: Psychotherapy", section on 'More introspective, higher functioning individuals'</a>.)</p><p></p><p class="headingAnchor" id="H2715686411"><span class="h2">Rationale for psychotherapy</span><span class="headingEndMark"> — </span>In our clinical experience, a psychodynamically informed, supportive, supportive-expressive or exploratory/insight-oriented psychotherapy is critical for patient stabilization and engagement in treatment.</p><p>Our recommendation is based primary on our clinical experience, which is consistent with the recommendations of others with expertise in the treatment of the disorder [<a href="#rid2">2,3</a>]. Our approach is also consistent with that of others who have described metacognitively oriented psychotherapeutic approaches (ie, approaches that focus on enhancing the development of more flexible and nuanced interpretations of thoughts, feelings, and intentions) to schizotypal personality disorder [<a href="#rid4">4,5</a>].</p><p>While there are theoretical and technical differences between psychodynamically informed and metacognitive psychotherapies, each places an emphasis on developing the ability to form complex and integrated ideas of self and others. These are then used in regulating distress and guiding responses to psychosocial challenges [<a href="#rid5">5</a>]. Both allow for the treatment to be tailored according to level of personality function.</p><p>There are no controlled clinical trials on the efficacy of psychotherapy for the disorder. Case series and reports have supported the use of metacognitively oriented therapy in the treatment of schizotypal personality disorder [<a href="#rid4">4,5</a>]. Techniques, goals, and choice of psychotherapy for individuals with schizotypal personality disorder are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/112012.html" rel="external">"Schizotypal personality disorder: Psychotherapy", section on 'Efficacy'</a> and  <a class="medical medical_review" href="/z/d/html/112012.html" rel="external">"Schizotypal personality disorder: Psychotherapy", section on 'Choosing psychotherapy'</a>.)</p><p class="headingAnchor" id="H724720434"><span class="h1">AS NEEDED SYMPTOM-TARGETED PHARMACOTHERAPY</span><span class="headingEndMark"> — </span>In our clinical experience, pharmacotherapy targeting certain core symptoms of schizotypal personality disorder can be a helpful adjunct to psychotherapy and can partially attenuate symptomatic manifestations. These core symptoms include cognitive-perceptual/psychotic symptoms, cognitive deficits, and social anxiety. (See <a class="local">'Cognitive-perceptual and psychotic symptoms'</a> below and <a class="local">'Cognitive deficits'</a> below and <a class="local">'Social anxiety'</a> below.)</p><p class="headingAnchor" id="H2757775710"><span class="h2">Counseling on medication use</span><span class="headingEndMark"> — </span>Individuals with schizotypal personality disorder can be highly ambivalent about medication. This can be exacerbated if the symptoms a psychiatrist recommends treating pharmacologically do not bother the patient. We use the following guidelines in the pharmacological management of individuals with schizotypal disorder.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Empathic clarification of false beliefs</strong> – We support empathic clarification and tactful confrontation of odd/magical or paranoid beliefs concerning medication. While a medication may be helpful, psychotherapeutically addressing ambivalence about the medication may be the more pressing issue.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Avoid excessive reliance on medication</strong> – We typically avoid excessive reliance on medications in treating schizotypal personality disorder. This is in part because the symptomatic manifestations (eg, social anxiety, attenuated emotional reactivity, and cognitive-perceptual symptoms) can be mistaken for other mental disorders that are more responsive to medication (eg, social anxiety disorder, major depression, psychotic disorders). The relatively indolent course of schizotypal personality disorder symptoms in general may also encourage an undue reliance on medication rather than psychotherapy. (See  <a class="medical medical_review" href="/z/d/html/112012.html" rel="external">"Schizotypal personality disorder: Psychotherapy", section on 'Chronicity of symptoms, indolent course'</a>.)</p><p></p><p class="headingAnchor" id="H1151248988"><span class="h2">Rationale for symptom-targeted pharmacotherapy</span><span class="headingEndMark"> — </span>There are no clinical trials comparing various pharmacologic approaches for symptoms of any of the domains. A handful of small clinical trials suggest that judicious, adjunctive use of medications for certain targeted symptoms of the disorder may partially reduce their severity. As an example, in a clinical trial, treatment with cognitive remediation, social skills training and <a class="drug drug_general" data-topicid="8510" href="/z/d/drug information/8510.html" rel="external">guanfacine</a> led to greater improvement in reasoning, problem solving, and social cognition than treatment with cognitive remediation, social skills training, and placebo [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H2073996206"><span class="h2">Cognitive-perceptual and psychotic symptoms</span><span class="headingEndMark"> — </span>We suggest adjunctive medication with an antipsychotic medication for individuals with schizotypal personality disorder with cognitive-perceptual symptoms that cause significant impairment and/or are highly ego-dystonic. (See <a class="local">'Antipsychotic medication'</a> below.)</p><p>Target symptoms in this domain include odd beliefs/magical thinking, unusual perceptual experiences, ideas of reference, and paranoia. They are generally chronic but can become more pronounced (eg, to a psychotic degree) under stress. (See  <a class="medical medical_review" href="/z/d/html/14771.html" rel="external">"Schizotypal personality disorder: Epidemiology, pathogenesis, clinical manifestations, course, and diagnosis", section on 'Cognitive-perceptual'</a>.)</p><p class="headingAnchor" id="H3411567952"><span class="h3">Antipsychotic medication</span><span class="headingEndMark"> — </span>In our clinical experience, low-dose atypical antipsychotics can attenuate clinically significant and ego-dystonic cognitive-perceptual symptoms and acute exacerbations of cognitive-perceptual symptoms. However, the presence of cognitive-perceptual symptoms in and of itself is not an indication for antipsychotic treatment. (See <a class="local">'Choice and administration of antipsychotic'</a> below.)</p><p>We prefer using antipsychotic treatment used within the context of treatment with psychotherapy. We focus on understanding how the patient makes sense of their symptoms, their thoughts, fears, and expectations about medication, as well as on processing of salient psychosocial events that may be precipitating these symptoms.</p><p class="headingAnchor" id="H229051118"><span class="h4">Choice and administration of antipsychotic</span><span class="headingEndMark"> — </span>As there do not appear to be significant differences in efficacy among antipsychotics (see <a class="local">'Efficacy'</a> below), we typically base our choice of antipsychotic medication on comorbid conditions, the patient’s risk factors for side effects, and the medication’s side effect profile. We generally use <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">aripiprazole</a>, <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">quetiapine</a>, <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">risperidone</a>, or <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a>, which have lower rates of extrapyramidal symptoms compared with first-generation antipsychotics, and have been studied in schizotypal personality disorder or have indications for comorbidities common to schizotypal personality disorder. (See  <a class="medical medical_review" href="/z/d/html/14776.html" rel="external">"Second-generation antipsychotic medications: Pharmacology, administration, and side effects", section on 'Adverse effects'</a>.)</p><p>Individuals with schizotypal personality disorder may be particularly sensitive to side effects. We often begin with a dose towards the lower end of the starting dose range. This is typically lower than dosing for acute psychosis and psychotic disorders  (<a class="graphic graphic_table graphicRef60624" href="/z/d/graphic/60624.html" rel="external">table 1</a>). We typically titrate in slowly (eg, increase the medication every two to three weeks), unless a more rapid pace is necessary due to the acuity and severity of co-occurring symptom. It is essential to engage patients in the process of titration.</p><p>As an example, <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">risperidone</a> can be started at 0.25 mg daily (at bedtime if insomnia is present) for at least two weeks, and increased to 0.5 mg daily if clinically indicated. Further dose changes should be determined on a case-by-case basis. Starting and therapeutic doses of other antipsychotic drugs for the disorder include:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">Aripiprazole</a> – 2 mg and 5 to 10 mg</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">Quetiapine</a> – 25 mg and 50 to 100 mg</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">Olanzapine</a> – 1.25 mg and 5 to 7.5 mg</p><p></p><p>We often continue antipsychotics medications for weeks to months if a transient exacerbation is targeted, or longer if chronic symptoms respond to treatment. The need for ongoing use should be reviewed with the patient approximately every three months and weighed against the side effects. (See <a class="local">'Side effects'</a> below.)</p><p class="headingAnchor" id="H3843952259"><span class="h4">Side effects</span><span class="headingEndMark"> — </span>Common side effects associated with second-generation antipsychotics include weight gain and related metabolic effects, extrapyramidal symptoms, hypotension, sedation, anticholinergic symptoms, hyperprolactinemia, cardiac effects, cardiomyopathies, cataracts, and sexual dysfunction. The rate and severity of these side effects and their treatment is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/14776.html" rel="external">"Second-generation antipsychotic medications: Pharmacology, administration, and side effects", section on 'Adverse effects'</a> and  <a class="medical medical_review" href="/z/d/html/14805.html" rel="external">"Schizophrenia in adults: Maintenance therapy and side effect management"</a>.)</p><p>The potential morbidity of metabolic effects has led to recommendations for routine short- and long-term monitoring of weight, waist circumference, blood pressure, fasting glucose, and lipid profile of patients taking any of the antipsychotic drugs  (<a class="graphic graphic_table graphicRef74435" href="/z/d/graphic/74435.html" rel="external">table 2</a>) [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/z/d/html/14805.html" rel="external">"Schizophrenia in adults: Maintenance therapy and side effect management"</a>.)</p><p class="headingAnchor" id="H1072464149"><span class="h4">Efficacy</span><span class="headingEndMark"> — </span>Limited clinical trial data suggest that antipsychotic medication may be useful as an adjunct to psychotherapy in schizotypal personality disorder.</p><p>Two small trials provide limited evidence that second-generation antipsychotics may be efficacious for symptoms of schizotypal personality.</p><p class="bulletIndent1"><span class="glyph">●</span>In a clinical trial, 25 individuals with schizotypal personality disorder were randomly assigned to receive <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">risperidone</a> (2 mg/day) or placebo for nine weeks [<a href="#rid8">8</a>]. Risperidone was titrated to 2 mg/day over seven weeks. Mean total scores on the Positive and Negative Symptoms Scale (PANSS) improved in the risperidone treated group compared with placebo. The negative and general PANSS subscales improved more quickly and/or at a lower antipsychotic dose (0.25 to 0.5 mg/day) compared with the positive-symptom subscale (1 to 2 mg/day).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An uncontrolled, open-label trial tested the efficacy of <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> (average dose 9.32 mg/day) on a range of psychiatric symptoms in 11 patients with schizotypal personality disorder [<a href="#rid9">9</a>]. After 26 weeks of treatment, mean scores on the Brief Psychiatric Rating scale and the Global Assessment Scale of overall patient functioning improved in 7 of the 11 individuals. Olanzapine was generally well tolerated; however, close to half of patients experienced more than a 7 percent increase in body weight.</p><p></p><p class="headingAnchor" id="H1816070950"><span class="h2">Cognitive deficits</span><span class="headingEndMark"> — </span>Cognitive deficits are very common in schizotypal personality disorder and are typically a function of deficits in working memory, executive function, and verbal memory. Cognitive deficits clinically manifest as absent mindedness, daydreaming, losing one’s train of thought, forgetfulness, losing/misplacing everyday items, poor time management, difficulty with organizing complex tasks, and trouble remembering verbally processed information. (See  <a class="medical medical_review" href="/z/d/html/14771.html" rel="external">"Schizotypal personality disorder: Epidemiology, pathogenesis, clinical manifestations, course, and diagnosis", section on 'Cognitive deficits'</a>.)</p><p class="headingAnchor" id="H3923127009"><span class="h3">Stimulants as preferred option</span><span class="headingEndMark"> — </span>Our first choice of medication to treat cognitive deficits in individuals with schizotypal disorder is a stimulant. However, because of the risks of misuse and addiction, stimulants are not recommended in patients with an active substance use disorder or history of a stimulant use disorder.</p><p>In our clinical experience, the cognitive deficits of schizotypal personality disorder can be treated effectively with stimulants at doses used for attention deficit hyperactivity disorder (ADHD).</p><p>A small, uncontrolled trial and our clinical experience suggest that stimulants may be effective in the treatment of cognitive deficits in patients with schizotypal personality disorder. As an example, a single dose of 30 mg of <a class="drug drug_general" data-topicid="99959" href="/z/d/drug information/99959.html" rel="external">amphetamine</a> was found to decrease perseverative errors on the Wisconsin Card Sorting Testing in nine patients [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H2221088215"><span class="h4">Administration</span><span class="headingEndMark"> — </span>We suggest starting with a low dose of a stimulant and titrating relatively slowly to allow for close clinical monitoring of efficacy and potential adverse reactions. As an example, long-acting <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a> (eg, Concerta or generic equivalents) can be started at 18 or 27 mg once per day in morning and increased by 18 mg/day at weekly intervals to a therapeutic range of 54 to 72 mg.</p><p>Due to risks of adverse cardiac events, prior to treatment with stimulants, patients should receive an evaluation for cardiovascular symptoms (eg, chest pain, palpitations and syncope), and measurement of blood pressure and pulse are recommended [<a href="#rid11">11</a>]. When findings outside of normal limits are seen, consultation with an internist or cardiologist is recommended to determine whether the findings are sufficiently severe to avoid these medications. Blood pressure and pulse should be monitored at regular intervals (eg, initially weekly, then monthly or bimonthly) over the course of stimulant treatment. (See  <a class="medical medical_review" href="/z/d/html/5763.html" rel="external">"Cardiac evaluation of patients receiving pharmacotherapy for attention deficit hyperactivity disorder", section on 'Pretreatment clinical evaluation'</a>.)</p><p class="headingAnchor" id="H2946406160"><span class="h4">Side effects</span><span class="headingEndMark"> — </span>Patients with schizotypal personality disorder theoretically have an increased risk of psychosis when treated with stimulants; cases have been reported in schizotypal personality disorder patients treated with a stimulant for co-occurring ADHD [<a href="#rid12">12</a>], but appear to be relatively rare. A neurobiological study in which patients with schizotypal personality disorder received an <a class="drug drug_general" data-topicid="99959" href="/z/d/drug information/99959.html" rel="external">amphetamine</a> challenge did not find the medication to be associated with psychotic reactions [<a href="#rid13">13-15</a>].</p><p>Side effects of stimulants reported in adults treated for ADHD include dry mouth, insomnia, edginess/irritability, dysphoria, diminished appetite, weight loss, and headaches [<a href="#rid16">16</a>]. (See  <a class="medical medical_review" href="/z/d/html/118534.html" rel="external">"Attention deficit hyperactivity disorder in adults: Treatment overview", section on 'Adverse effects'</a>.)</p><p>Other serious, less common adverse effects seen in adults treated with stimulants for ADHD include cardiovascular events [<a href="#rid11">11,17</a>], priapism [<a href="#rid18">18-20</a>], and congenital cardiac malformations in children born to women treated with <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a> during pregnancy [<a href="#rid21">21</a>].</p><p>Prescription stimulants are subject to misuse, addiction, and/or diversion in some patients. Patients with a recent or current substance use disorder are believed to be as higher risk. Misuse of prescription drugs, including stimulants, is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/15236.html" rel="external">"Prescription drug misuse: Epidemiology, prevention, identification, and management", section on 'Stimulants'</a>.)</p><p class="headingAnchor" id="H1925072072"><span class="h3">Guanfacine as alternative</span><span class="headingEndMark"> — </span>Extended-release <a class="drug drug_general" data-topicid="8510" href="/z/d/drug information/8510.html" rel="external">guanfacine</a>, an alpha-2a adrenergic agonist used in the treatment of ADHD, is an option, particularly for patients with a contraindication to a stimulant or who fail to respond to initial trial of a stimulant.</p><p><a class="drug drug_general" data-topicid="8510" href="/z/d/drug information/8510.html" rel="external">Guanfacine</a> can be started at 0.5 mg twice daily, and increased to 1.5 to 2 mg twice as tolerated, if needed, at a rate of 0.5 mg twice daily per week; guanfacine extended release is started at 1 mg/day (usually in the evening), advancing after one to two weeks in 1 mg increments, up to a maximum of 4 mg/day as needed and tolerated. To enhance tolerability, dosing of guanfacine extended release can be twice daily. (See  <a class="medical medical_review" href="/z/d/html/118534.html" rel="external">"Attention deficit hyperactivity disorder in adults: Treatment overview", section on 'Treatments with limited supporting data in adult ADHD'</a>.)</p><p>Side effects of <a class="drug drug_general" data-topicid="8510" href="/z/d/drug information/8510.html" rel="external">guanfacine</a> included hypotension, tachycardia, headache, fatigue, abdominal pain, constipation, and sedation [<a href="#rid22">22</a>].</p><p>In individuals with schizotypal personality disorder, <a class="drug drug_general" data-topicid="8510" href="/z/d/drug information/8510.html" rel="external">guanfacine</a> may be helpful in improving working memory, as well as lead to improvements in reasoning, problem solving and social cognition. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In a randomized clinical trial of 29 patients with schizotypal personality disorder, treatment with 2 mg/day of <a class="drug drug_general" data-topicid="8510" href="/z/d/drug information/8510.html" rel="external">guanfacine</a> (an alpha-2a adrenergic receptor agonist) was shown to improve performance on a context processing task, which reflects working memory ability [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a randomized clinical trial of 28 patients with schizotypal personality disorder receiving an eight-week course of computerized cognitive remediation and social skills training, the addition of 2 mg/day of <a class="drug drug_general" data-topicid="8510" href="/z/d/drug information/8510.html" rel="external">guanfacine</a> led to improved reasoning, problem solving scores, and measures of social cognition as compared to individuals receiving similar treatment combined with placebo [<a href="#rid6">6</a>].</p><p></p><p class="headingAnchor" id="H2441945585"><span class="h2">Social anxiety</span><span class="headingEndMark"> — </span>Social anxiety, a prominent and difficult to treat feature of schizotypal personality disorder, has not been subject to clinical trials of medication efficacy in schizotypal personality disorder patients.</p><p>For most patients with schizotypal personality disorder and prominent social anxiety, we suggest adjunctive treatment with a long-acting benzodiazepine. In our clinical experience, social anxiety in patients with schizotypal personality disorder does not appear to respond robustly to a selective serotonin reuptake inhibitor (SSRI), the first-line medication treatment for social anxiety disorder. However, an SSRI or serotonin-norepinephrine reuptake inhibitor is a reasonable alternative in patients with an active substance use disorder or history of a benzodiazepine use disorder or in patients with coexisting depression or anxiety disorder. <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">Gabapentin</a> is another potential option.</p><p>In our experience, a long-acting benzodiazepine such as <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">clonazepam</a> appears to be effective, albeit partially, when taken as a standing daily dose (rather than as needed) for social anxiety in schizotypal personality disorder. As an example, clonazepam can be started at 0.25 mg twice daily, and titrated at a rate of 0.25 to 0.5 mg day or week according to efficacy and tolerability, to a maximum dose of 3 to 4 mg/day.</p><p>Side effects of benzodiazepines include impairment of psychomotor performance, amnesia, addiction, and withdrawal symptoms after long-term treatment, and rebound anxiety after short-term treatment. Benzodiazepines should not be used in those with an active substance use disorder or a history of benzodiazepine use disorder.</p><p class="headingAnchor" id="H431941270"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117525.html" rel="external">"Society guideline links: Psychotic disorders"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/122640.html" rel="external">"Society guideline links: Personality disorders"</a>.)</p><p class="headingAnchor" id="H775831634"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Psychotherapy </strong>–<strong> </strong>For individuals with schizotypal personality disorder, we suggest first-line treatment with a long-term psychodynamically informed psychotherapy rather than pharmacotherapy alone (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Psychotherapy as the primary intervention'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Selection of psychotherapy</strong> – We base our choice of psychotherapy for individuals with schizotypal personality disorder on the individual’s level of impairment, ability to critically examine thoughts, and capacity to tolerate negative emotions. There are no trials comparing different psychotherapeutic approaches in patients with schizotypal personality disorder. (See <a class="local">'Selection of psychotherapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For individuals who have limited capacity to critically exam thoughts and are poorly functioning we favor treatment with supportive psychotherapy. (See <a class="local">'Selection of psychotherapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For individuals who have a modest ability to critically examine thoughts, emotions or behaviors, we favor supportive-expressive psychotherapy. (See <a class="local">'Selection of psychotherapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For individuals who have greater ability to critically examine thoughts and are higher functioning, we favor a modified exploratory/insight-oriented approach. (See <a class="local">'Selection of psychotherapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptom-targeted pharmacotherapy</strong> – In our clinical experience, pharmacotherapy targeting certain core symptoms of schizotypal personality disorder can be a helpful adjunct to psychotherapy. Pharmacologic management can partially attenuate symptomatic manifestations of schizotypal personality disorder. (See <a class="local">'As needed symptom-targeted pharmacotherapy'</a> above.)</p><p></p><p class="bulletIndent1">Individuals with schizotypal personality disorder can be highly ambivalent about medication. This can be exacerbated if the symptoms that being addressed pharmacologically are not particularly bothersome to the individual. In order to minimize this we clarify the reason we are choosing to use medications, address odd/magical or paranoid beliefs about medications, and avoid excessive reliance on medication.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For individuals with schizotypal personality disorder with cognitive-perceptual symptoms that cause significant impairment or distress, and/or are highly ego-dystonic, we suggest adjunctive treatment with low dose atypical antipsychotic medication rather than other medications (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Cognitive-perceptual and psychotic symptoms'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For most individuals with schizotypal personality disorder with prominent cognitive deficits, we suggest adjunctive treatment with a stimulant medication (eg, long-acting <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a>) rather than other medications (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). <a class="drug drug_general" data-topicid="8510" href="/z/d/drug information/8510.html" rel="external">Guanfacine</a> is a reasonable alternative for patients with an active substance use disorder or a history of a stimulant use disorder, or who did not respond to a stimulant. (See <a class="local">'Cognitive deficits'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For most individuals with schizotypal personality disorder with prominent social anxiety, we suggest adjunctive treatment with a standing (rather than “as needed”) dose of the benzodiazepine, <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">clonazepam</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). A selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor is a reasonable alternative in patients with an active substance use disorder or history of a benzodiazepine use disorder. (See <a class="local">'Social anxiety'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Nielsen KD, Hovmand OR, Jørgensen MS, et al. Psychotherapy for patients with schizotypal personality disorder: A scoping review. Clin Psychol Psychother 2023; 30:1264.</a></li><li><a class="nounderline abstract_t">Stone M. Schizotypal personality: psychotherapeutic aspects. Schizophr Bull 1985; 11:576.</a></li><li><a class="nounderline abstract_t">Treatment outlines for paranoid, schizotypal and schizoid personality disorders. The Quality Assurance Project. Aust N Z J Psychiatry 1990; 24:339.</a></li><li><a class="nounderline abstract_t">Cheli S. Assessment and treatment planning for schizotypal personality disorder: A metacognitively oriented point of view. Psychiatr Rehabil J 2020; 43:335.</a></li><li><a class="nounderline abstract_t">Cheli S, Lysaker PH, Dimaggio G. Metacognitively oriented psychotherapy for schizotypal personality disorder: A two-case series. Personal Ment Health 2019; 13:155.</a></li><li><a class="nounderline abstract_t">McClure MM, Graff F, Triebwasser J, et al. Guanfacine Augmentation of a Combined Intervention of Computerized Cognitive Remediation Therapy and Social Skills Training for Schizotypal Personality Disorder. Am J Psychiatry 2019; 176:307.</a></li><li><a class="nounderline abstract_t">American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27:596.</a></li><li><a class="nounderline abstract_t">Koenigsberg HW, Reynolds D, Goodman M, et al. Risperidone in the treatment of schizotypal personality disorder. J Clin Psychiatry 2003; 64:628.</a></li><li><a class="nounderline abstract_t">Keshavan M, Shad M, Soloff P, Schooler N. Efficacy and tolerability of olanzapine in the treatment of schizotypal personality disorder. Schizophr Res 2004; 71:97.</a></li><li><a class="nounderline abstract_t">Siegel BV Jr, Trestman RL, O'Flaithbheartaigh S, et al. D-amphetamine challenge effects on Wisconsin Card Sort Test. Performance in schizotypal personality disorder. Schizophr Res 1996; 20:29.</a></li><li><a class="nounderline abstract_t">Schelleman H, Bilker WB, Kimmel SE, et al. Methylphenidate and risk of serious cardiovascular events in adults. Am J Psychiatry 2012; 169:178.</a></li><li><a class="nounderline abstract_t">Bramness JG, Gundersen ØH, Guterstam J, et al. Amphetamine-induced psychosis--a separate diagnostic entity or primary psychosis triggered in the vulnerable? BMC Psychiatry 2012; 12:221.</a></li><li><a class="nounderline abstract_t">Woodward ND, Cowan RL, Park S, et al. Correlation of individual differences in schizotypal personality traits with amphetamine-induced dopamine release in striatal and extrastriatal brain regions. Am J Psychiatry 2011; 168:418.</a></li><li><a class="nounderline abstract_t">Wonodi I, Cassady SL, Adami H, et al. Effects of repeated amphetamine administration on antisaccade in schizophrenia spectrum personality. Psychiatry Res 2006; 141:237.</a></li><li><a class="nounderline abstract_t">Abi-Dargham A, Kegeles LS, Zea-Ponce Y, et al. Striatal amphetamine-induced dopamine release in patients with schizotypal personality disorder studied with single photon emission computed tomography and [123I]iodobenzamide. Biol Psychiatry 2004; 55:1001.</a></li><li><a class="nounderline abstract_t">Santosh PJ, Sattar S, Canagaratnam M. Efficacy and tolerability of pharmacotherapies for attention-deficit hyperactivity disorder in adults. CNS Drugs 2011; 25:737.</a></li><li><a class="nounderline abstract_t">Wender PH. Pharmacotherapy of attention-deficit/hyperactivity disorder in adults. J Clin Psychiatry 1998; 59 Suppl 7:76.</a></li><li><a class="nounderline abstract_t">Kelly BD, Lundon DJ, McGuinness D, Brady CM. Methylphenidate-induced erections in a prepubertal child. J Pediatr Urol 2013; 9:e1.</a></li><li><a class="nounderline abstract_t">Cakin-Memik N, Yildiz O, Sişmanlar SG, et al. Priapism associated with methylphenidate: a case report. Turk J Pediatr 2010; 52:430.</a></li><li><a class="nounderline abstract_t">Schwartz RH, Rushton HG. Stuttering priapism associated with withdrawal from sustained-release methylphenidate. J Pediatr 2004; 144:675.</a></li><li><a class="nounderline abstract_t">Huybrechts KF, Bröms G, Christensen LB, et al. Association Between Methylphenidate and Amphetamine Use in Pregnancy and Risk of Congenital Malformations: A Cohort Study From the International Pregnancy Safety Study Consortium. JAMA Psychiatry 2018; 75:167.</a></li><li><a class="nounderline abstract_t">Biederman J, Melmed RD, Patel A, et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 2008; 121:e73.</a></li><li><a class="nounderline abstract_t">McClure MM, Barch DM, Romero MJ, et al. The effects of guanfacine on context processing abnormalities in schizotypal personality disorder. Biol Psychiatry 2007; 61:1157.</a></li></ol></div><div id="topicVersionRevision">Topic 116590 Version 11.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37675964" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Psychotherapy for patients with schizotypal personality disorder: A scoping review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4081651" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Schizotypal personality: psychotherapeutic aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2241718" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Treatment outlines for paranoid, schizotypal and schizoid personality disorders. The Quality Assurance Project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32463252" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Assessment and treatment planning for schizotypal personality disorder: A metacognitively oriented point of view.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31169366" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Metacognitively oriented psychotherapy for schizotypal personality disorder: A two-case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30654644" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Guanfacine Augmentation of a Combined Intervention of Computerized Cognitive Remediation Therapy and Social Skills Training for Schizotypal Personality Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14747245" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Consensus development conference on antipsychotic drugs and obesity and diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12823075" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Risperidone in the treatment of schizotypal personality disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15374577" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Efficacy and tolerability of olanzapine in the treatment of schizotypal personality disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8794491" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : D-amphetamine challenge effects on Wisconsin Card Sort Test. Performance in schizotypal personality disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22318795" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Methylphenidate and risk of serious cardiovascular events in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23216941" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Amphetamine-induced psychosis--a separate diagnostic entity or primary psychosis triggered in the vulnerable?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21159728" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Correlation of individual differences in schizotypal personality traits with amphetamine-induced dopamine release in striatal and extrastriatal brain regions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16500713" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Effects of repeated amphetamine administration on antisaccade in schizophrenia spectrum personality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15121484" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Striatal amphetamine-induced dopamine release in patients with schizotypal personality disorder studied with single photon emission computed tomography and [123I]iodobenzamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21870887" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Efficacy and tolerability of pharmacotherapies for attention-deficit hyperactivity disorder in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9680056" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Pharmacotherapy of attention-deficit/hyperactivity disorder in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22552161" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Methylphenidate-induced erections in a prepubertal child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21043394" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Priapism associated with methylphenidate: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15127013" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Stuttering priapism associated with withdrawal from sustained-release methylphenidate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29238795" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Association Between Methylphenidate and Amphetamine Use in Pregnancy and Risk of Congenital Malformations: A Cohort Study From the International Pregnancy Safety Study Consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18166547" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16950221" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The effects of guanfacine on context processing abnormalities in schizotypal personality disorder.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
